Table 2.
Molecular features of analyzed patients
| Molecular features | Specification | All | LTS (n = 91) | STS-1 (n = 91) | LTS (subgroup, n = 80) | STS-2 (n = 80) |
|---|---|---|---|---|---|---|
| GFAP* (%) | Positive | 73.8 | 94.4 | 61.6 | 93.5 | 64.6 |
| Partially negative | 25.2 | 5.6 | 37.0 | 6.5 | 33.8 | |
| Negative | 1.0 | 0 | 1.4 | 0 | 1.5 | |
| MGMT* (%) | Methylated | 53.7 | 70.9 | 49.0 | 71.1 | 37.2 |
| Unmethylated | 46.3 | 29.1 | 51.0 | 28.9 | 62.8 | |
| IDH1R132H* (%) | Positive | 11.0 | 15.4 | 7.3 | 16.7 | 11.9 |
| Negative | 89.0 | 84.6 | 92.7 | 83.3 | 88.1 | |
| MIB1 |
Median (range) |
20 (3–90) |
18 (5–60) |
25 (8–50) |
18 (5–60) |
25 (3–90) |
| Ki67 |
Median (range) |
25 (8–90) |
20 (8–60) |
30 (10–90) |
25 (10–60) |
25 (10–80) |
| Ki67/MIB1 |
Median (range) |
25 (3–90) |
18 (5–60) |
30 (8–90) |
20 (5–60) |
25 (3–90) |
| GFAP/MGMT* (%) | GFAP+/MGMT+ | 42 | 66.0 | 28.6 | 65.9 | 25.0 |
| GFAP+/MGMT− | 34 | 30.2 | 35.7 | 29.5 | 37.5 | |
| GFAP−/MGMT+ | 10 | 3.8 | 16.7 | 4.5 | 12.5 | |
| GFAP−/MGMT− | 13 | 0 | 19.0 | 0 | 25.0 |
*Results refer to patients in whom tissue was available